Low Back Pain: Do Guidelines Get it Right?

March 13th 2025

Obesity & Pain Management: A Primary Viewpoints Podcast

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.

April 27th 2023

FDA Approves Expanded Use for Sublocade for Opioid Use Disorder

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

Patient Care Editorial Staff

February 24th 2025

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.

September 29th 2022

Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose

AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.

FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update

Your daily dose of the clinical news you may have missed.

Related Content

March 13th 2025

Obesity & Pain Management: A Primary Viewpoints Podcast

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.

April 27th 2023

FDA Approves Expanded Use for Sublocade for Opioid Use Disorder

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

Patient Care Editorial Staff

February 24th 2025

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.

September 29th 2022

Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose

AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.